Final savings for the Finance & Accounting for Bioscience West conference ends soon. Register by Friday, November 13 to save $200 on your pass.
Biocom member Informa will host its inaugural event December 7–8 at the Hilton La Jolla Torrey Pines. The forum will bring together bioss and senior finance leaders to tackle shifting board expectations, capital allocation strategies and commercial launch readiness. Attendees will also explore how finance teams are leveraging AI and enterprise readiness planning (ERP) tools to improve forecasting accuracy and maintain audit readiness. View the full program: bit.ly/4zxsKog
Secure your registration before rates increase November 13.
Register: bit.ly/4BYwzES
Biocom member Informa will host its inaugural event December 7–8 at the Hilton La Jolla Torrey Pines. The forum will bring together bioss and senior finance leaders to tackle shifting board expectations, capital allocation strategies and commercial launch readiness. Attendees will also explore how finance teams are leveraging AI and enterprise readiness planning (ERP) tools to improve forecasting accuracy and maintain audit readiness. View the full program: bit.ly/4zxsKog
Secure your registration before rates increase November 13.
Register: bit.ly/4BYwzES
0
0
0
50
This week in Bay Area life sciences: #Corcept reports positive Phase 2 BELLA trial results for lifyorli in combination with nab-paclitaxel and bevacizumab for the treatment of platinum-resistant ovarian cancer. @FrontierMeds presents promising anti-tumor activity from Phase 1/2 FMC-376 in the treatment of KRAS G12C-mutant non-small cell lung cancer. @IdeayaB27412 presents updated Phase 1 results demonstrating promising antitumor activity of IDE849 in relapsed small cell lung cancer and neuroendocrine carcinomas. #MTNRefrigeration shares preventive maintenance strategies to reduce refrigeration failures, downtime and batch losses in lyophilization processes. Subscribe to receive the next newsletter in your inbox: bit.ly/40rlR8a
0
0
0
75
2026 Biocom Catalyst Award winner Kevin Caldwell, co-founder and CEO of Ossium Health, is advancing stem cell products for patients with hematological diseases. Read his story: bit.ly/4icTYug #BiocomCatalystAwards
0
0
0
59
Biocom actively connects innovators, clinicians and developers across the medtech industry to share practical insights, address integration hurdles and translate emerging technologies into real-world patient outcomes. Bringing members together around these shared challenges helps logy sector collaborative, resilient and focused on meaningful clinical impact.
Interested in learning more? Biocom’s Medical Device & Diagnostics Committee will convene November 17 in San Diego to explore spatial biology and AI-driven workflows.
Register: bit.ly/4ikXEJe
Interested in learning more? Biocom’s Medical Device & Diagnostics Committee will convene November 17 in San Diego to explore spatial biology and AI-driven workflows.
Register: bit.ly/4ikXEJe
0
0
1
56
In this month's Regulatory & Reimbursement Newsletter: The FDA launches the Neuroscience Advancement Innovation Nexus program, CMS issues a proposed rule implementing the Consolidated Appropriations Act, 2026 on Medicare Advantage, California receives more than $233 million in RuraProgram funding and more. Read it here: bit.ly/4v7W8zz
0
0
1
62
This week in San Diego life sciences: @AlumeBioscience announces the FDA accepted its new drug application for bevonescein for use during surgery. Atrium Therapeutics doses the first patient in the Corventis clinical trial for the treatment of PRKAG2 syndrome. @neurocrine establishing a benchmark for clinically meaningful health changes in patients with tardive dyskinesia. @scrippsresearch receives a $16.4 million NIH award to establish a multi-institutional hepatitis C vaccine development center. Subscribe to receive the next newsletter in your inbox: bit.ly/4iqn5b1
0
0
0
78
On December 3 at 10 a.m., Biocom will host a virtual discussion on how data-intensive, automated workflows are reshaping modern laboratory space. Industry experts will break down structural design considerations, emerging facility automation applications and operational case esigned for professionals managing, planning or building life science facilities, this session will highlight practical strategies to prepare environments for the next wave of computational research.
Register: bit.ly/4iiCmMc
Register: bit.ly/4iiCmMc
0
0
0
69
What does it take to go from scientist to biotech entrepreneur?
Join @theNCI SBIR program November 10 at 11 a.m. PST for a webinar exploring how training, mentorship and networks support biotech commercialization.
Register: bit.ly/3UsR9w9
Join @theNCI SBIR program November 10 at 11 a.m. PST for a webinar exploring how training, mentorship and networks support biotech commercialization.
Register: bit.ly/3UsR9w9
0
0
0
84
2026 Biocom Catalyst Award winner Anastasia Budinskaya of NFX backs founders advancing the future of women’s health. Read her story: bit.ly/4iaxRoj #BiocomCatalystAwards
0
0
0
192
More runway. Less overhead. Biocom members save an average of 25x their annual dues through 30+ group purchasing programs covering lab supplies, logistics, employee benefits and more.
Explore membership: bit.ly/4yIbDyY
#MedTech
Explore membership: bit.ly/4yIbDyY
#MedTech
0
0
0
78
It's #NewMemberMonday! #4JTherapeutics designs broad-spectrum antiviral agents on a programmable drug discovery platform that targets conserved viral RNA structures to treat influenza and other viral infections. #AvalorTherapeutics advances tissue-targeted disease-modifying nflammatory conditions, with lead programs in osteoarthritis and refractory gout. #Bettani unites plant-based brands built on its Caseed technology, including cream cheeses, dairy-free mozzarella and plant proteins for foodservice. #MycaZEDTherapeutics develops antifungal treatments that inhibit chitin synthase, an enzyme needs to build their cell walls, to treat infections while sparing human cells. #PortonUSA provides end-to-end development and GMP manufacturing services across small molecules, biologics and advanced therapies from research to commercial launch. @sandiegozoo integrates wildlife health, science and education across its zoo and safari park to develop sustainable global conservation solutions.
0
0
0
114
Thank you to @AsmMaggyKrell for visiting @OrcaBio's Sacramento facility! Biotech continues to expand in the region, bringing quality jobs and economic growth to her district every year.
Orca Bio recently received FDA approval for TREGZI (Orca-T), its first commercial product. ere this therapy is manufactured, right here in Sacramento, offered an incredible look at the innovation taking place across the state.
We are grateful to the Orca Bio team for opening their doors and sharing their work, and we thank Assemblymember Krell for taking the time to learn how California’s life science organizations are advancing new treatment options for patients.
Biocom looks forward to continuing our work with the Assemblymember and her office to support a policy environment where life science innovation can thrive in California.
Orca Bio recently received FDA approval for TREGZI (Orca-T), its first commercial product. ere this therapy is manufactured, right here in Sacramento, offered an incredible look at the innovation taking place across the state.
We are grateful to the Orca Bio team for opening their doors and sharing their work, and we thank Assemblymember Krell for taking the time to learn how California’s life science organizations are advancing new treatment options for patients.
Biocom looks forward to continuing our work with the Assemblymember and her office to support a policy environment where life science innovation can thrive in California.
0
1
0
121
2026 Biocom Catalyst Award winner Aarash Bordbar, CEO of Sinopia Biosciences, uses computational biology to advance drug discovery. Read his story: bit.ly/48oa7qQ #BiocomCatalystAwards
0
0
0
104
Catch the most recent Group Purchasing Newsletter to learn more about how to safeguard your organization from a cyberattack with @centrexIT's Cyber Crisis Day After Report, @SunaSolutions' breakdown of the key phases of managed service provider deployment, @Dotcompliance_'s study outlining its process in replacing Codis' legacy systems with a unified cloud-based eQMS and more. Read the full edition: bit.ly/3TYRUgk
0
0
0
67
2026 Biocom Catalyst Award winner Sarah Allard of @UCSD Soil Health Center explores how microbial communities shape our world, from the human body to agricultural plants and soils. Read her story: bit.ly/4iK2gKj #BiocomCatalystAwards
0
0
0
93
Companies importing from overseas often tie up substantial capital in customs duties and fees, expenses which seem wasted when imported goods are later exported, returned or destroyed. However, in these specific situations, these duties may be recoverable.
Join Biocom and ovember 10, at 11 a.m. for a virtual introduction to duty drawback, an often forgotten method of recovering these funds. Designed for trade compliance, supply chain, finance, procurement and global operations leaders, this session will cover practical strategies to streamline the duty drawback process, identify tariff recovery opportunities and reclaim up to 99% of duties already paid.
Register: bit.ly/4yLbrz6
Join Biocom and ovember 10, at 11 a.m. for a virtual introduction to duty drawback, an often forgotten method of recovering these funds. Designed for trade compliance, supply chain, finance, procurement and global operations leaders, this session will cover practical strategies to streamline the duty drawback process, identify tariff recovery opportunities and reclaim up to 99% of duties already paid.
Register: bit.ly/4yLbrz6
0
0
0
68
This week in Bay Area life sciences: @GileadSciences reports positive Phase 2 SWIFT study results for emvistegrast for the treatment of ulcerative colitis. #IDEAYABiosciences and Servier present clinical trial data supporting darovasertib as a potential foundational therapy in melanoma. @RevMedicines doses the first patients in the Phase 3 RASolve 308 trial evaluating zoldonrasib in a first-line treatment of metastatic RAS G12D non-squamous non-small cell lung cancer. Subscribe to receive the next newsletter in your inbox: bit.ly/40rlR8a
0
0
0
145
The market has shifted. Has your capital strategy?
Join us on November 4 for the next installment of our San Diego CFO series, where leaders from @Crinetics, @EYnews and #latigobiotherapeutics will examine IPO readiness, M&A, private capital and other paths to growth or liquopportunity to explore what separates companies that are positioned to act from those that aren't and how leaders can preserve optionality in a rapidly changing market. Register: bit.ly/3WTrkWE
Thank you to our sponsors: @DFINSolutions, @EYnews, @JLL, @jpmorgan. @Marsh_MMA, @SayvaSolutions and #Stout.
Join us on November 4 for the next installment of our San Diego CFO series, where leaders from @Crinetics, @EYnews and #latigobiotherapeutics will examine IPO readiness, M&A, private capital and other paths to growth or liquopportunity to explore what separates companies that are positioned to act from those that aren't and how leaders can preserve optionality in a rapidly changing market. Register: bit.ly/3WTrkWE
Thank you to our sponsors: @DFINSolutions, @EYnews, @JLL, @jpmorgan. @Marsh_MMA, @SayvaSolutions and #Stout.
0
0
0
86
Last call: Applications for 1:1 meetings with Servier’s External Innovation Team close November 6.
On December 9, Servier Pharmaceuticals will hold in-person partnering meetings in South San Francisco. Servier is seeking partners across four priority areas:
🔹 Oncology assets rs and hematologic malignancies
🔹 Neurology programs in rare movement and neuromuscular disorders, refractory epilepsies and other rare neurological disorders
🔹 AI and digital technologies supporting R&D, clinical development, pharmaceutical operations and patient care
🔹 Enabling technologies spanning therapeutic platforms, drug delivery, advanced biological models, biomarkers, imaging and manufacturing
Opportunities may include asset licensing, external research agreements and regionally focused partnerships.
Applications close November 6, 11:59 p.m. PST: bit.ly/4zeeOiK
On December 9, Servier Pharmaceuticals will hold in-person partnering meetings in South San Francisco. Servier is seeking partners across four priority areas:
🔹 Oncology assets rs and hematologic malignancies
🔹 Neurology programs in rare movement and neuromuscular disorders, refractory epilepsies and other rare neurological disorders
🔹 AI and digital technologies supporting R&D, clinical development, pharmaceutical operations and patient care
🔹 Enabling technologies spanning therapeutic platforms, drug delivery, advanced biological models, biomarkers, imaging and manufacturing
Opportunities may include asset licensing, external research agreements and regionally focused partnerships.
Applications close November 6, 11:59 p.m. PST: bit.ly/4zeeOiK
0
0
0
94
This week in San Diego life sciences: @FateThx presents updated preliminary data on FT819 for the treatment of active lupus nephritis. #ThaumatecTechGroup has expanded its offerings to provide end-to-end software services for medical devices, supporting medtech companies from regulatory compliance through postmarket maintenance and product evolution. @TravereRare presents new biomarker data suggesting FILSPARI may modify disease pathophysiology in IgA nephropathy. @ZentalisP reports median overall survival data in cyclin E1-positive, platinum-resistant ovarian cancer from DENALI Part 1b. Subscribe to receive the next newsletter in your inbox: bit.ly/4iqn5b1
0
0
0
112